Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,409 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02933320 | BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia | completed | Phase 1 / Phase 2 | 14 | Cancer Research UKOTHER | 1 | Jul 8, 2021 | clinicaltrials |
| NCT00109707 | A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies | completed | Phase 1 / Phase 2 | 507 | Novartis PharmaceuticalsINDUSTRY | 22 | Jun 29, 2021 | clinicaltrials |
| NCT04082286 | Yttrium-90 Anti CD66 Monoclonal Antibody in Childhood Relapsed/Refractory Leukaemia | completed | Phase 1 | 9 | Great Ormond Street Hospital for Children NHS Foundation TrustOTHER | 1 | Jun 25, 2021 | clinicaltrials |
| NCT02043899 | A Phase I/II Study of [124I]mIBG PET/CT in Neuroblastoma | completed | Phase 1 / Phase 2 | 36 | Cancer Research UKOTHER | 1 | Jun 21, 2021 | clinicaltrials |
| NCT01211483 | Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer | completed | Phase 1 / Phase 2 | 222 | Daiichi SankyoINDUSTRY | 13 | Jun 16, 2021 | clinicaltrials |
| NCT03669601 | AZD6738 & Gemcitabine as Combination Therapy(ATRiUM) | unknown | Phase 1 | 55 | CCTU- Cancer ThemeOTHER | 1 | Jun 4, 2021 | clinicaltrials |
| NCT02118337 | A Phase 1/2, Open-label Study to Evaluate the Safety and Antitumor Activity of MEDI0680 (AMP-514) in Combination With Durvalumab Versus Nivolumab Monotherapy in Participants With Select Advanced Malignancies | completed | Phase 1 / Phase 2 | 97 | MedImmune LLCINDUSTRY | 6 | Jun 1, 2021 | clinicaltrials |
| NCT02669017 | Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL) | completed | Phase 1 | 183 | ADC Therapeutics S.A.INDUSTRY | 3 | May 19, 2021 | clinicaltrials |
| NCT02303912 | Safety and Efficacy Study of Nuc-1031 and Carboplatin Combination to Treat Recurrent Ovarian Cancer(ProGem2) | completed | Phase 1 | 25 | Imperial College Healthcare NHS TrustOTHER | 1 | May 18, 2021 | clinicaltrials |
| NCT02055690 | PAZOFOS: Phase Ib and Phase II Trial of Pazopanib +/- Fosbretabulin in Advanced Recurrent Ovarian Cancer(PAZOFOS) | terminated | Phase 1 / Phase 2 | 21 | The Christie NHS Foundation TrustOTHER | 1 | May 17, 2021 | clinicaltrials |
| NCT01693562 | A Phase 1/2 Study to Evaluate MEDI4736 | completed | Phase 1 / Phase 2 | 1,022 | MedImmune LLCINDUSTRY | 9 | May 13, 2021 | clinicaltrials |
| NCT02028117 | Phase I / Dose Expansion Study of Enadenotucirev in Ovarian Cancer Patients(OCTAVE) | completed | Phase 1 | 38 | Akamis BioINDUSTRY | 2 | May 13, 2021 | clinicaltrials |
| NCT01271504 | E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | completed | Phase 1 / Phase 2 | 102 | Eisai Inc.INDUSTRY | 6 | May 12, 2021 | clinicaltrials |
| NCT03298763 | Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer(TACTICAL) | unknown | Phase 1 / Phase 2 | 46 | University College, LondonOTHER | 1 | Apr 28, 2021 | clinicaltrials |
| NCT02433392 | Study of Intraparenchymal Therapy as Adjunct Therapy in Patients With Recurrent, Resectable Glioblastoma Multiforme. | terminated | Phase 1 | 9 | Boston Scientific CorporationINDUSTRY | 1 | Apr 21, 2021 | clinicaltrials |
| NCT02545907 | A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis(CATALYST) | completed | Phase 1 / Phase 2 | 10 | University College, LondonOTHER | 1 | Apr 15, 2021 | clinicaltrials |
| NCT03328494 | Study of Paclitaxel in Combination With BOS172722 in Patients With Advanced Nonhaematologic Malignancies | completed | Phase 1 | 38 | Boston PharmaceuticalsINDUSTRY | 1 | Apr 15, 2021 | clinicaltrials |
| NCT01251640 | Combination With Gemcitabine in Advanced Pancreatic Cancer(BAGPAC) | completed | Phase 1 / Phase 2 | 90 | BayerINDUSTRY | 9 | Apr 8, 2021 | clinicaltrials |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | completed | Phase 1 / Phase 2 | 33 | Seagen Inc.INDUSTRY | 5 | Apr 8, 2021 | clinicaltrials |
| NCT01659255 | Study to Evaluate the Safety and Tolerability of Tirabrutinib (ONO/GS-4059) Given as Monotherapy in Participants With Relapsed/Refractory NHL and CLL | completed | Phase 1 | 90 | Gilead SciencesINDUSTRY | 2 | Mar 16, 2021 | clinicaltrials |
| NCT02372006 | Trial of Afatinib in Pediatric Tumours | completed | Phase 1 / Phase 2 | 56 | Boehringer IngelheimINDUSTRY | 12 | Mar 4, 2021 | clinicaltrials |
| NCT00306202 | Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia | completed | Phase 1 | 63 | Bristol-Myers SquibbINDUSTRY | 6 | Feb 26, 2021 | clinicaltrials |
| NCT04397705 | Remote Monitoring of Cancer Patients With Suspected Covid-19(RECAP) | unknown | Phase 1 | 30 | The Christie NHS Foundation TrustOTHER | 1 | Feb 11, 2021 | clinicaltrials |
| NCT03289455 | CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell Acute Lymphoblastic Leukemia (ALL)(AMELIA) | completed | Phase 1 / Phase 2 | 23 | Autolus LimitedINDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT04675021 | Absolute Bioavailability and ADME Study of Savolitinib in Healthy Male Subjects | completed | Phase 1 | 8 | AstraZenecaINDUSTRY | 1 | Jan 26, 2021 | clinicaltrials |
| NCT02593045 | Study of IPH4102 in Patients With Relapsed/Refractory Cutaneous T-cell Lymphomas (CTCL) | completed | Phase 1 | 44 | Innate PharmaINDUSTRY | 4 | Jan 20, 2021 | clinicaltrials |
| NCT04546347 | A Study to Assess the Rel Bioavailability, Food Effect and Absolute Bioavailability on the Pharmacokinetics of AZD9833 | completed | Phase 1 | 32 | AstraZenecaINDUSTRY | 1 | Jan 20, 2021 | clinicaltrials |
| NCT02044120 | ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP Inhibitor, Niraparib and Temozolomide and/or Irinotecan Patients With Previously Treated, Incurable Ewing Sarcoma | completed | Phase 1 | 34 | Sarcoma Alliance for Research through CollaborationOTHER | 2 | Jan 12, 2021 | clinicaltrials |
| NCT01323530 | A Confirmation Study of Eribulin in Combination With Capecitabine | completed | Phase 1 / Phase 2 | 76 | Eisai LimitedINDUSTRY | 3 | Jan 11, 2021 | clinicaltrials |
| NCT03205046 | A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies | terminated | Phase 1 / Phase 2 | 25 | Acerta Pharma BVINDUSTRY | 2 | Jan 6, 2021 | clinicaltrials |
| NCT03342859 | Mode of Action Study of Vilaprisan and Ulipristal Acetate in Patients With Uterine Fibroids for Whom Surgery is Planned | terminated | Phase 1 | 10 | BayerINDUSTRY | 1 | Jan 6, 2021 | clinicaltrials |
| NCT01077544 | A Pharmacokinetic (PK) Study of Nilotinib in Pediatric Patients With Philadelphia Chromosome-positive (Ph+) Chronic Myelogenous Leukemia (CML) or Acute Lymphoblastic Leukemia (ALL) | completed | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 29, 2020 | clinicaltrials |
| NCT01468688 | A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients | completed | Phase 1 | 60 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 21, 2020 | clinicaltrials |
| NCT01482156 | Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors | completed | Phase 1 | 46 | Novartis PharmaceuticalsINDUSTRY | 7 | Dec 21, 2020 | clinicaltrials |
| NCT01735968 | A Dose-finding Study of a Combination of Imatinib and BYL719 in the Treatment of 3rd Line GIST Patients | completed | Phase 1 | 56 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 21, 2020 | clinicaltrials |
| NCT00880308 | Dose Finding and Safety of Oral LDE225 in Patients With Advanced Solid Tumors | completed | Phase 1 | 103 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT00997399 | Study to Evaluate Panobinostat (DACi) Pharmacokinetics and Safety in Solid Tumors and Varying Renal Function | completed | Phase 1 | 37 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT01007968 | Pharmacokinetics and Safety of Panobinostat in Patients With Advanced Solid Tumors and Various Degrees of Hepatic Function | completed | Phase 1 | 25 | Novartis PharmaceuticalsINDUSTRY | 5 | Dec 19, 2020 | clinicaltrials |
| NCT01402440 | Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma | terminated | Phase 1 | 15 | Novartis PharmaceuticalsINDUSTRY | 10 | Dec 19, 2020 | clinicaltrials |
| NCT01430416 | Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients | completed | Phase 1 | 153 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 19, 2020 | clinicaltrials |
| NCT01487785 | Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 19, 2020 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT01602406 | Phase I Study LJM716 Combined With Trastuzumab in Patients With HER2 Overexpressing Metastatic Breast or Gastric Cancer | completed | Phase 1 | 64 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT01822613 | Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) | completed | Phase 1 | 48 | Novartis PharmaceuticalsINDUSTRY | 9 | Dec 19, 2020 | clinicaltrials |
| NCT02925104 | A Dose Escalation Study to Assess PK, Safety and Tolerability of INC280 When Taken With Food in cMET Dysregulated Advanced Solid Tumors. | completed | Phase 1 | 36 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT00526045 | Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients | completed | Phase 1 / Phase 2 | 117 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT00670592 | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prior Therapies | completed | Phase 1 / Phase 2 | 111 | Novartis PharmaceuticalsINDUSTRY | 11 | Dec 17, 2020 | clinicaltrials |
| NCT01106508 | A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors | completed | Phase 1 | 57 | Novartis PharmaceuticalsINDUSTRY | 4 | Dec 17, 2020 | clinicaltrials |
| NCT02088684 | Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer | completed | Phase 1 | 70 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 17, 2020 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials